To inhibit the HER2/HER3 pathway, we used lapatinib, a reversible, ATP-competitive tyrosine kinase inhibitor of HER2 that has been approved for treatment of HER2+ BC for a decade. This evidence concerns the gene ERBB2 and breast cancer.